PacBio (PACB) Q1 Earnings In Line, Adjusted Gross Margin Up [Yahoo! Finance]
Pacific Biosciences of California, Inc. (PACB)
Last pacific biosciences of california, inc. earnings: 2/6 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.pacificbiosciences.com
Company Research
Source: Yahoo! Finance
The adjusted loss per share aligned with the Zacks Consensus Estimate. The company's GAAP loss per share was 29 cents in the quarter, narrower than the year-ago period's loss of 36 cents. Revenues in Detail PacBio registered revenues of $38.8 million in the first quarter, down 0.2% year over year. The figure beats the Zacks Consensus Estimate by 0.08%. Geographical Analysis PacBio's revenues from the Americas were $17.7 million, down 7% year over year. This was primarily due to a decline in Revio shipments. In the Asia-Pacific region, PacBio recorded revenues of $12.8 million, reflecting a 7% uptick year over year. Europe, the Middle East and Africa (EMEA) region registered revenues of $8.4 million, which rose 6% year over year. Segmental Analysis Product revenues amounted to $35 million, up 1.02% from the year-ago quarter. PacBio shipped 28 Revio sequencing systems in the first quarter, which brought the company's installed base to 201 Revio systems as of Mar 31, 20
Show less
Read more
Impact Snapshot
Event Time:
PACB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PACB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PACB alerts
High impacting Pacific Biosciences of California, Inc. news events
Weekly update
A roundup of the hottest topics
PACB
News
- Pacific Biosciences of California, Inc. (NASDAQ: PACB) had its price target lowered by analysts at Morgan Stanley from $10.00 to $4.00. They now have an "equal weight" rating on the stock.MarketBeat
- Ambry Genetics and PacBio Announce Collaboration to Sequence Up to 7,000 Human Genomes Aimed at Providing Answers for Families Battling Rare Diseases [Yahoo! Finance]Yahoo! Finance
- Ambry Genetics and PacBio Announce Collaboration to Sequence Up to 7,000 Human Genomes Aimed at Providing Answers for Families Battling Rare DiseasesPR Newswire
- Pacific Biosciences of California, Inc. (NASDAQ: PACB) was upgraded by analysts at StockNews.com to a "sell" rating.MarketBeat
- Pacific Biosciences of California, Inc. (NASDAQ: PACB) had its price target lowered by analysts at Piper Sandler from $6.50 to $2.00. They now have a "neutral" rating on the stock.MarketBeat
PACB
Earnings
- 5/9/24 - In-Line
PACB
Sec Filings
- 5/9/24 - Form S-3ASR
- 5/9/24 - Form 10-Q
- 5/9/24 - Form 8-K
- PACB's page on the SEC website